2025 Annual Meeting | Industry Therapeutic Update from UCB, Inc.: Earlier Identification and Treatment of Patients with a Developmental and Epileptic Encephalopathy (DEE): Taking A Close Look at Lennox-Gastaut Syndrome (LGS)

Date Saturday 04/05/25

Time 11:45 AM - 12:45 PM PDT Add To Calendar

Location San Diego Convention Center | 6B

Session Format This program will be presented in-person only

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Industry Therapeutic Update

Director(s) Heidi L. Henninger, MD, FAAN, David E. Burdette, MD, Michael Chez, MD, FAAN

Topic(s) General Neurology

Learning Objectives Representing 1% to 2% of all epilepsies, Lennox-Gastaut syndrome (LGS) is a drug-resistant developmental and epileptic encephalopathy (DEE) associated with a wide range of etiologies. The evolving nature of LGS, its seizure types, and EEG patterns make the diagnosis of LGS challenging. Join us in an expert-led panel discussion where you will learn from epileptologists on how to identify patients with LGS in your practice, when to refer, and current treatment developments. In addition, hear unique perspectives from a patient advocate on the burden of LGS and the potential impact of delayed diagnosis and treatment.
This program is NOT accredited for continuing education by any organization. Additionally, Industry Therapeutic Updates program content and the views expressed herein are those of the presenting corporate entity and not of the AAN. These programs are not an official part of the 2025 AAN Annual Meeting education or scientific programs, nor are they endorsed by the AAN. The AAN cannot affirm claims pertaining to FDA off-label medication, research use of pre-FDA drugs, or other research information that might be discussed. Industry Therapeutic Updates are industry events.

CME Available No CME available

Program Materials Program Evaluations

Event Timeline
11:45 AM - 12:45 PM PDT	Speaker	Industry Therapeutic Update from UCB, Inc.: Earlier Identification and Treatment of Patients with a Developmental and Epileptic Encephalopathy (DEE): Taking A Close Look at Lennox-Gastaut Syndrome (LGS)

Faculty Disclosures
Michael Chez, MD, FAAN	Dr. Chez has received personal compensation in the range of $500-$4,999 for serving as a Consultant for ucb. Dr. Chez has received personal compensation in the range of $500-$4,999 for serving as a Consultant for marinus. Dr. Chez has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Catalyst. Dr. Chez has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurelsi. Dr. Chez has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for SK Pharma. Dr. Chez has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ucb. Dr. Chez has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Catalyst.
David E. Burdette, MD	Dr. Burdette has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Jazz Pharmaceuticals. Dr. Burdette has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Catalyst. Dr. Burdette has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Jazz Pharmaceuticals. Dr. Burdette has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for SK Life pharmaceuticals. Dr. Burdette has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for NeuroPace. Dr. Burdette has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for UCB. The institution of Dr. Burdette has received research support from Longboard. The institution of Dr. Burdette has received research support from NeuroPace.
Heidi L. Henninger, MD, FAAN	Dr. Henninger has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB.

��ɫ��

��ɫ��